
TWST Stock Forecast & Price Target
TWST Analyst Ratings
Bulls say
Twist Bioscience Corp has raised its gross margin guidance for FY25 to 49.5%, up from the previous estimate of 49%, and anticipates surpassing 50% gross margins by the end of Q4 FY25, indicating solid operational performance and profitability potential. The company has maintained its revenue guidance for FY25 while also increasing its adjusted EBITDA outlook, showcasing robust financial health and growth prospects. Furthermore, management believes that the upcoming spin-off will enhance visibility towards achieving adjusted EBITDA profitability, further strengthening the positive outlook for the company's financial future.
Bears say
Twist Bioscience Corp has reported that its data business has consistently posed a significant headwind to its adjusted EBITDA, with an impact of approximately $5 million per quarter. This ongoing drag on financial performance raises concerns about the profitability and operational efficiency of the company's overall business model. The recurring negative contributions from the data segment suggest persistent challenges that may hinder the company's financial growth and investor confidence moving forward.
This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares